GlassScriptPhysician profile
Owen Bennet Schneider
NPI 1184798852
$3,339.69
in general payments reported to CMS, 2019-2025
23 companies · $41.25 in 2025
The $41.25 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,594 · 2020: $504 · 2022: $21.45 · 2023: $85.33 · 2024: $94.41 · 2025: $41.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $220.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $599.62 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $519.19 | 2019-2024 | Trintellix |
| Shire North American Group INC | $315.64 | 2019 | |
| Allergan, INC. | $298.07 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $259.46 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $186.00 | 2019-2020 | |
| Bausch Health US, LLC | $179.24 | 2019-2020 | |
| Corium, LLC | $153.28 | 2022-2024 | Azstarys |
| Neos Therapeutics, LP | $148.01 | 2019-2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $129.45 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $93.20 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $86.57 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $63.06 | 2019 | |
| Adlon Therapeutics L.P. | $61.03 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $51.24 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $41.25 | 2025 | Loreev Xr |
| Orexo US, INC. | $33.69 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $32.18 | 2019 | |
| Alkermes, INC. | $30.84 | 2019 | |
| Ironshore Pharmaceuticals INC. | $22.78 | 2019 | |
| Indivior INC. | $12.81 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.13 | 2019 | |
| Currax Pharmaceuticals LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Owen Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.